Study authors assessed the efficacy and safety of cefiderocol vs best available therapy in adults with serious carbapenem-resistant Gram-negative infections.
Researchers compared the efficacy and safety of cefiderocol vs high-dose, extended-infusion meropenem for adults with nosocomial pneumonia.
Although hypercoagulability has been reported in critically ill patients with COVID-19, results from a small study revealed that these patients did not have a higher prevalence of pulmonary embolism compared to patients without COVID-19.
Study authors described the prescribing patterns in children with community-acquired pneumonia, and assessed the relationship between narrow-spectrum antibiotics, broad-spectrum antibiotics, and macrolides with clinical outcomes.
The effect of appropriate antimicrobial therapy on 14-day mortality in patients severely ill with Acinetobacter baumannii bacteremic pneumonia was assessed, taking risk factors, patient demographics, and clinical characteristics into account.
Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114.
Study authors assessed pneumococcal urinary antigen testing’s use in identifying patients for broad-spectrum antibiotic de-escalation, providing an opportunity for improved antimicrobial stewardship.
Researchers linked the use of 2 hypertension drug classes to lower mortality for those hospitalized with flu and pneumonia.
Pneumomediastinum, although a rare phenomenon, is more prevalent in patients with COVID-19 compared with historical patients with adult respiratory distress syndrome.
Patients with severe COVID-19 pneumonia had improved prognosis after receiving a short course of methyl-prednisolone pulses during the second week of disease.
